EMBLA.CO
BuyFull HouseAI neutralEmbla Medical hf. · Healthcare · Iceland · $1.8B
DKK 26.65 +0.2% · close 5 Oct · scored 7 Oct
Full House: Strong business, sensible price, market agrees. The rare full house.
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Embla Medical (formerly Ossur) is a global leader in prosthetics and bracing, backed by strong clinician relationships, reimbursement know-how and a growing patient-care clinic network. The business is a good-quality compounder, and it is running a steady buyback. Forward estimates have been trimmed slightly, however, and no current catalyst suggests growth will accelerate.
ABOUT EMBLA MEDICAL HF.
Read
Embla Medical hf (formerly Össur hf) is a global leader in non-invasive orthopaedics, specializing in the development and manufacture of advanced prosthetics, bracing, and support solutions. The company holds a strong market position, particularly in bionic prosthetic technologies that utilize microprocessors to mimic natural limb movement. Embla Medical benefits from high barriers to entry due to extensive patent protection, clinical validation requirements, and established relationships with prosthetic clinics worldwide.
FINANCIAL SUMMARY (DKK)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.8B | 5.2B | 5.7B | 6.2B | 8.9% | 6.5B | 6.8B | 7.3B | 8.7% |
| EPS (DKK) | 0.68 | 0.93 | 1.08 | 1.30 | 23.9% | 1.46 | 1.62 | 1.86 | 19.6% |
| Shares | 420.3M | 420.3M | 426.9M | 427.8M | +1.8% | 425.3M | — | — | — |
| Debt | 3.2B | 3.1B | 3.3B | 3.6B | 4.0% | 3.5B | — | — | — |
| Equity | 4.2B | 4.7B | 5.2B | 5.9B | 11.9% | — | — | — | — |
| Op CF | 404.0M | 627.0M | 771.5M | 881.6M | 29.7% | 950.2M | — | — | — |
| Inv CF | -440.5M | -379.9M | -696.4M | -306.6M | — | — | — | — | — |
| Fin CF | 25.2M | -272.3M | 38.3M | -497.1M | — | — | — | — | — |
Calmer than 80% of stocks we rank over the past year (26% a year).
How this is worked out
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of EMBLA.CO are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| EMBLA.CO | Embla Medical hf.(you) | $1.8B | 78 | Buy |
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.